SLC5A2 and Duchenne muscular dystrophy: Despite advances in pharmacologic treatments in the adult heart failure field, there is still a critical gap in DMD care, mainly in the transition phase, due to the limited evidence with the utilization of novel therapies such as sodium-glucose cotransporter 2 inhibitors (SGLT2is) and angiotensin receptor-neprilysin inhibitors (ARNIs) in DMD setting.